New treatment modalities and pharmacologic refinements for metatstatic breast cancer
(Nieuwe cytotoxische behandelingen en farmacokinetiek van paclitaxel bij de gemetastaseerd mammacarcinoom)
2002-06-21
Doctoral Thesis
| Related Files |
|---|
View PDF Version
(020621_Smorenburg, Carolina Henriëtte.pdf, 0.6MB) |
|
View PDF Version
(Cover.pdf, 0.2MB) |
|
View PDF Version
(stellingen Smorenburg.pdf, 0.0MB) |
In this thesis the results of clinical studies with new chemotherapeutic agents and pharmacokinetic studies on taxanes in breast cancer patients are reported. In metastatic breast cancer, endocrine and cytotoxic treatment often result in objective tumor responses, associated with relevant relief of symptoms. At present, however, metastatic breast cancer is still considered to be incurable even despite agressive multi-modality treatment options. Chemotherapy for metastatic breast cancer should therefore aim at a maximum of palliation and prolongation of life, at the cost of a minimal of toxicity.
Supervisor
(promotor):
Keywords
Automatically Extracted Terms
- patient
- cancer
- paclitaxel
- study
- breast
- metastatic breast cancer
- docetaxel
- phase
- combination
- metastatic
- capecitabine
- oncol
- gemcitabine
- pharmacokinetic
- treatment
- toxicity
- breast cancer
- chapter
- agent
- phase i study
